SCHEMBL207659

SCHEMBL207659

Clc1ccc2[nH][c]nc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F7 P08709 2/20 0.42
F3 P13726 2/20 0.42
DYRK1A Q13627 2/20 0.42
AHR P35869 2/20 0.41
NR4A2 P43354 2/20 0.41
LTA4H P09960 1/20 0.41
NOS1 P29475 2/20 0.38
ALDH1A1 P00352 4/20 0.36
HPGD P15428 2/20 0.36
PSMB8 P28062 2/20 0.36
HSD17B10 Q99714 2/20 0.36
CMA1 P23946 1/20 0.36
POLB P06746 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
HAVCR2 Q8TDQ0 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GRIN1 Q05586 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207168 0.83 ALDH1A1 (0.44) F7F3DYRK1AAHRNOS1
SCHEMBL28796612 0.81 JAK2 (0.48) BACE1
SCHEMBL208893 0.75 KDM4E (0.36) AHRALDH1A1KDM4EMAPTKMT2A
SCHEMBL5981619 0.75 DYRK1A (0.42) DYRK1AALDH1A1HPGDPOLBHTR3A
SCHEMBL206867 0.75 NOS1 (0.38) DYRK1AAHRNR4A2NOS1ALDH1A1
SCHEMBL7221951 0.75 ALDH1A1 (0.42) ALDH1A1HPGDPOLBALOX15KDM4E
SCHEMBL7186585 0.75 ALDH1A1 (0.49) ALDH1A1HPGDHSD17B10KDM4EMEN1
SCHEMBL440275 0.74 MAPK13 (0.41) DYRK1AALDH1A1HPGDHSD17B10TSHR
SCHEMBL27864312 0.73 MAP4K4 (0.44) BACE1
SCHEMBL208230 0.73 LMNA (0.42) F7F3DYRK1AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118201911-A Compounds and their use as GPR183 inhibitors 南京艾美斐生物医药科技有限公司 2024-06-14 CN claimed
CN-116438160-A Carbamoyl compounds for the treatment of viral infections 豪夫迈·罗氏有限公司 2023-07-14 CN claimed
EP-4204393-A1 AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2023-07-05 EP claimed
EP-3386973-B1 PESTICIDALLY ACTIVE 1,2,4-TRIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2020-08-12 EP claimed
EP-2809668-B1 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2017-04-12 EP claimed
US-9266876-B2 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2016-02-23 US claimed
EP-2362775-B1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2015-08-05 EP claimed
US-20140371204-A1 4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2014-12-18 US claimed
EP-2809668-A1 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2014-12-10 EP claimed
US-8697685-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2014-04-15 US claimed
WO-2004018431-A2 NOVEL PHENANTHRIDINES ALTANA PHARMA AG (DE) 2004-03-04 WO claimed
EP-1392639-A1 PYRUVATE DERIVATIVES Galileo Laboratories, Inc. (US) 2004-03-03 EP claimed
US-20030203897-A1 2,4-Disubstituted thiazolyl derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2003-10-30 US claimed
US-20030013847-A1 Cytoprotective agents MONSANTO TECHNOLOGY LLC 2003-01-16 US claimed
EP-1261607-A1 2,4-DISUBSTITUTED THIAZOLYL DERIVATIVES Janssen Pharmaceutica N.V. (BE) 2002-12-04 EP claimed
WO-2002090314-A1 PYRUVATE DERIVATIVES GALILEO LABORATORIES, INC. (US) 2002-11-14 WO claimed
WO-2001064674-A1 2,4-DISUBSTITUTED THIAZOLYL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2001-09-07 WO claimed
WO-2000061631-A1 MODIFIED PENTAPEPTIDE ANTAGONISTS OF THE ATRIAL NATRIURETIC PEPTIDE CLEARANCE RECEPTOR ASTRAZENECA AB (SE) 2000-10-19 WO claimed
CN-1225013-A Non-peptide G-CSF mimetics SMITHKLINE BEECHAM CORP (US) 1999-08-04 CN claimed
EP-0335646-A1 Antiviral compounds SYNPHAR LABORATORIES INC. (CA) 1989-10-04 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013847-A1 Cytoprotective agents PC, PDK1, PDK2 F7 4236/4885F3 810/4885DYRK1A 1197/4885
US-20030203897-A1 2,4-Disubstituted thiazolyl derivatives IL4, PTGER4, PTGER1 F7 2582/4885F3 1049/4885DYRK1A 3232/4885
US-20140371204-A1 4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives CXCR3, CXCR1, CXCR2 F7 3884/4885F3 1461/4885DYRK1A 1712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.